J.P. Morgan Maintains Neutral on Amicus Therapeutics (FOLD) - Amicus Therapeutics (NASDAQ:FOLD)

Crypto Whales Are Loading Up — Are You?

New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.

J.P. Morgan is out with its report today on Amicus Therapeutics (NASDAQ: FOLD), maintaining Neutral.In a note to clients, J.P. Morgan writes, "We are Neutral on FOLD shares. Amicus' chaperone technology is a unique platform in biotech that could offer treatment for a wide range of diseases, including Fabry disease and Parkinson's disease. Longer term we think there is a good probability that Amigal for Fabry disease will be successful, and we expect other earlier stage compounds to move forward. However, we think the announcement that Plicera failed a phase 2 study in Gaucher disease was a negative announcement that may increase the discount on Amicus' technology until data from other programs are made available."At the time of posting, shares of FOLD were trading at $7.26, up 0.69% from Monday's close.

Crypto Whales Are Loading Up — Are You?

ENTER TO WIN $500 IN STOCK OR CRYPTO

Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!